Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$12.8 million.

  • Ovid Therapeutics' Cash from Operations rose 1453.32% to -$12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.0 million, marking a year-over-year increase of 3436.11%. This contributed to the annual value of -$56.0 million for FY2024, which is 2232.15% down from last year.
  • Ovid Therapeutics' Cash from Operations amounted to -$12.8 million in Q3 2025, which was up 1453.32% from -$4.8 million recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Cash from Operations peaked at $160.9 million during Q1 2021, and registered a low of -$20.1 million during Q1 2022.
  • In the last 5 years, Ovid Therapeutics' Cash from Operations had a median value of -$12.0 million in 2021 and averaged -$3.5 million.
  • The largest annual percentage gain for Ovid Therapeutics' Cash from Operations in the last 5 years was 97389.45% (2021), contrasted with its biggest fall of 63988.13% (2021).
  • Ovid Therapeutics' Cash from Operations (Quarter) stood at -$12.0 million in 2021, then increased by 23.53% to -$9.2 million in 2022, then decreased by 29.81% to -$11.9 million in 2023, then increased by 15.61% to -$10.1 million in 2024, then fell by 27.6% to -$12.8 million in 2025.
  • Its last three reported values are -$12.8 million in Q3 2025, -$4.8 million for Q2 2025, and -$10.3 million during Q1 2025.